Core Viewpoint - The company, Jinxin Reproductive Medicine (01951.HK), anticipates a loss of up to RMB 1.09 billion in the first half of 2025, following a profit of approximately RMB 190 million in the first half of 2024. This loss is primarily attributed to impairment and provisions related to goodwill, intangible assets, and other financial assets concerning its operations in the United States and Laos [1]. Financial Performance - The expected loss for the first half of 2025 is projected to be no more than RMB 1.09 billion [1]. - The company reported a profit of around RMB 190 million for the first half of 2024 [1]. Impairment and Provisions - The anticipated loss is mainly due to the recognition of impairment and provisions for certain goodwill, intangible assets, and other financial assets [1]. - The company has conducted a careful assessment of its operational and financial performance, as well as the future prospects of its business, to determine the necessity and extent of the impairments and provisions [1]. - The actual amounts for impairment and provisions will require further evaluation by the company before they can be finalized [1].
锦欣生殖(01951.HK)发盈警 预计中期亏损不超10.9亿元